{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:59:37Z","timestamp":1772135977960,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To analyze the effectiveness and toxicities of radiotherapy in indolent non-Hodgkin\u2019s lymphoma (iNHL) patients treated in our institution. Patients with iNHL treated with radiotherapy between 1999 and 2016 were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were local control (LC), overall survival (OS) and toxicities. PFS, LC, and OS were analyzed using Kaplan\u2013Meier method. Log-rank test was used to investigate the differences between subgroups. Cox proportional hazard model was used for univariate continuous analysis. Seventy-five patients were identified in our institutional database between 1999 and 2016. Fifty-eight (77.3%) had stage I after Ann-Arbor and 17 patients (22.7%) had stage II. The median follow-up was 87\u00a0months (95% CI 72\u2013102\u00a0months). Median single dose per fraction was 2.0\u00a0Gy (range 1.5\u20132\u00a0Gy) and median total dose was 30.6\u00a0Gy (range 16\u201345\u00a0Gy). Radiotherapy was performed in 2D (n\u2009=\u200910; 13.3%), 3D (n\u2009=\u200963; 84.0%) and VMAT (n\u2009=\u20092; 2.7%) techniques, respectively. The median PFS was 14.0\u00a0years (95% CI 8.3\u201319.7\u00a0years). The estimated PFS after 5 and 10\u00a0years were 73.0% and 65.5% in Kaplan\u2013Meier analysis, respectively. The 5- and 10-year LC were 94.9% and 92.3%, respectively. The 5- and 10-year OS were 88.6% and 73.9%. In univariate analyses of PFS, younger patients (\u2264\u200960\u00a0years old) had significantly superior PFS to those older than 60\u00a0years old (5-year PFS 81.9% vs. 65.1%, p\u2009=\u20090.021). Dose escalation\u2009&gt;\u200936.0\u00a0Gy had no prognostic influence in term of PFS (p\u2009=\u20090.425). Extranodal involvement, stage and histology had no prognostic impact on PFS. Depending on the site of lymphomas, the most common acute side effects were: dermatitis CTCAE\u00b0 I\u2013II (8.0%), xerostomia CTC\u00b0 I (8.0%), cataract CTC\u00b0 I (12.0%) and dry eyes CTC\u00b0 I\u2013II (14.6%). No adverse event CTC\u00b0 III was reported. Most acute side effects recovered at 3 to 6\u00a0months after radiotherapy except for CTC\u00b0 I cataract and xerostomia. Local Radiotherapy was highly effective for treatment of early stage iNHL with no serious side effects in our cohort. The most acute CTCAE\u00b0 I\u2013II side effects recovered 3 to 6\u00a0months later. Technique advances seem to have further improved effectiveness and tolerability of radiotherapy.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    Local ethics committee of Ludwig-Maximilian-University (LMU) Munich approved this retrospective analysis on the May 7th, 2019 (Nr. 19\u2013137).\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-01851-w","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T06:02:53Z","timestamp":1637301773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin\u2019s lymphoma: a monocenter analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"I.","family":"Hadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Eze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bodensohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Roengvoraphoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"1851_CR1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. (IARC Lyon, 2017).","edition":"4"},{"key":"1851_CR2","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RLM Haas","year":"2003","unstructured":"Haas, R. L. M. et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J. Clin. Oncol. 21, 2474\u20132480. https:\/\/doi.org\/10.1200\/JCO.2003.09.542 (2003).","journal-title":"J. Clin. Oncol."},{"key":"1851_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3322\/caac.21330","volume":"66","author":"M Raderer","year":"2016","unstructured":"Raderer, M., Kiesewetter, B. & Ferreri, A. J. M. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J. Clin. 66, 152\u2013171. https:\/\/doi.org\/10.3322\/caac.21330 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"1851_CR4","unstructured":"Zelenetz, A. D. et al. NCCN Guidelines Version 7.2019 B-Cell Lymphomas (2019)."},{"key":"1851_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400","author":"M Dreyling","year":"2016","unstructured":"Dreyling, M. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdw400 (2016).","journal-title":"Ann. Oncol."},{"key":"1851_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca, E. et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 17\u201329. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.010 (2020).","journal-title":"Ann. Oncol."},{"key":"1851_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-016-0690-y","volume":"11","author":"M Zimmermann","year":"2016","unstructured":"Zimmermann, M. et al. Radiotherapy for Non-Hodgkin\u2019s lymphoma: Still standard practice and not an outdated treatment option. Radiat. Oncol. 11, 1\u201310. https:\/\/doi.org\/10.1186\/s13014-016-0690-y (2016).","journal-title":"Radiat. Oncol."},{"key":"1851_CR8","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1002\/cncr.29491","volume":"121","author":"JA Vargo","year":"2015","unstructured":"Vargo, J. A., Gill, B. S., Balasubramani, G. K. & Beriwal, S. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer 121, 3325\u20133334. https:\/\/doi.org\/10.1002\/cncr.29491 (2015).","journal-title":"Cancer"},{"key":"1851_CR9","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","volume":"36","author":"Q Shi","year":"2018","unstructured":"Shi, Q. et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: An individual patient-level analysis of multiple randomized trials (SEAL). J. Clin. Oncol. 36, 2593\u20132602. https:\/\/doi.org\/10.1200\/JCO.2018.77.9124 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1851_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling, M. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008 (2021).","journal-title":"Ann. Oncol."},{"key":"1851_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3857\/roj.2015.33.4.310","volume":"33","author":"SH Choi","year":"2015","unstructured":"Choi, S. H. et al. Radiotherapy as an effective treatment modality for follicular lymphoma: A single institution experience. Radiat. Oncol. J. 33, 310\u2013319. https:\/\/doi.org\/10.3857\/roj.2015.33.4.310 (2015).","journal-title":"Radiat. Oncol. J."},{"key":"1851_CR12","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg, J. W. et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National Lymphocare Study. J. Clin. Oncol. 30, 3368\u20133375. https:\/\/doi.org\/10.1200\/JCO.2011.40.6546 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1851_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo, B. A. et al. Long-term outcome and mortality trends in early-stage, Grade 1\u20132 follicular lymphoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 64, 928\u2013934. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.08.010 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1851_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","volume":"104","author":"MS Binkley","year":"2019","unstructured":"Binkley, M. S. et al. Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: A Collaborative Study on Behalf of ILROG. Int. J. Radiat. Oncol. Biol. Phys. 104, 522\u2013529. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.004 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1851_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00066-009-1937-4","volume":"185","author":"HT Eich","year":"2009","unstructured":"Eich, H. T. et al. Long-term outcome and prognostic factors in early-stage nodal low-grade non-Hodgkin\u2019s lymphomas treated with radiation therapy. Strahlenther. Onkol. 185, 288\u2013295. https:\/\/doi.org\/10.1007\/s00066-009-1937-4 (2009).","journal-title":"Strahlenther. Onkol."},{"key":"1851_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"MP Mac Manus","year":"1996","unstructured":"Mac Manus, M. P. & Hoppe, R. T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J. Clin. Oncol. 14, 1282\u20131290. https:\/\/doi.org\/10.1200\/JCO.1996.14.4.1282 (1996).","journal-title":"J. Clin. Oncol."},{"key":"1851_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/bjc.1994.213","volume":"69","author":"HB Vaughan","year":"1994","unstructured":"Vaughan, H. B. et al. Clinical stage 1 non-Hodgkin\u2019s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br. J. Cancer 69, 1088\u20131093 (1994).","journal-title":"Br. J. Cancer"},{"key":"1851_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","volume":"51","author":"RB Wilder","year":"2001","unstructured":"Wilder, R. B. et al. Long-term results with radiotherapy for stage I\u2013II follicular lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 51, 1219\u20131227. https:\/\/doi.org\/10.1016\/S0360-3016(01)01747-3 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1851_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-8-2","volume":"8","author":"K Deinbeck","year":"2013","unstructured":"Deinbeck, K., Geinitz, H., Haller, B. & Fakhrian, K. Radiotherapy in marginal zone lymphoma. Radiat. Oncol. 8, 1\u20135. https:\/\/doi.org\/10.1186\/1748-717X-8-2 (2013).","journal-title":"Radiat. Oncol."},{"key":"1851_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21203\/rs.3.rs-28812\/v1","volume":"15","author":"KH Choi","year":"2020","unstructured":"Choi, K. H. et al. Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma. Radiat. Oncol. 15, 1\u20138. https:\/\/doi.org\/10.21203\/rs.3.rs-28812\/v1 (2020).","journal-title":"Radiat. Oncol."},{"key":"1851_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2407-11-87","volume":"11","author":"M Witzens-Harig","year":"2011","unstructured":"Witzens-Harig, M., Hensel, M., Unterhalt, M. & Herfarth, K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer 11, 2\u20137. https:\/\/doi.org\/10.1186\/1471-2407-11-87 (2011).","journal-title":"BMC Cancer"},{"key":"1851_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/hs9.0000000000000160","volume":"6","author":"K Herfarth","year":"2018","unstructured":"Herfarth, K. et al. Rituximab with involved field irradiation for early-stage nodal follicular lymphoma. HemaSphere 6, 1. https:\/\/doi.org\/10.1097\/hs9.0000000000000160 (2018).","journal-title":"HemaSphere"},{"key":"1851_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","volume":"94","author":"M Ruella","year":"2016","unstructured":"Ruella, M. et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I\u2013II follicular lymphoma: Results of a multicenter study. Int. J. Radiat. Oncol. Biol. Phys. 94, 783\u2013791. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.019 (2016).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1851_CR24","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus, M. et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular Lymphoma: TROG 99.03. J. Clin. Oncol. 36, 2918\u20132925. https:\/\/doi.org\/10.1200\/JCO.2018.77.9892 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1851_CR25","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1002\/cncr.25117","volume":"116","author":"BA Campbell","year":"2010","unstructured":"Campbell, B. A. et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 116, 3797\u20133806. https:\/\/doi.org\/10.1002\/cncr.25117 (2010).","journal-title":"Cancer"},{"key":"1851_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00066-020-01624-w","volume":"196","author":"L K\u00f6nig","year":"2020","unstructured":"K\u00f6nig, L. et al. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. Strahlenther. Onkol. 196, 705\u2013714. https:\/\/doi.org\/10.1007\/s00066-020-01624-w (2020).","journal-title":"Strahlenther. Onkol."},{"key":"1851_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry, L. et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiother. Oncol. 100, 86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013 (2011).","journal-title":"Radiother. Oncol."},{"key":"1851_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin, P. J. et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial. Lancet Oncol. 15, 457\u2013463. https:\/\/doi.org\/10.1016\/S1470-2045(14)70036-1 (2014).","journal-title":"Lancet Oncol."},{"key":"1851_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hon.2538","volume":"36","author":"P Ciammella","year":"2018","unstructured":"Ciammella, P., Luminari, S., Arcaini, L. & Filippi, A. R. Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications. Hematol. Oncol 36, 723\u2013732. https:\/\/doi.org\/10.1002\/hon.2538 (2018).","journal-title":"Hematol. Oncol"},{"key":"1851_CR30","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani, R., Rosenberg, S. A. & Horning, S. J. Stage I and II follicular non-Hodgkin\u2019s lymphoma: Long-term follow-up of no initial therapy. J. Clin. Oncol. 22, 1454\u20131459. https:\/\/doi.org\/10.1200\/JCO.2004.10.086 (2004).","journal-title":"J. Clin. Oncol."},{"key":"1851_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady, J. L. et al. Definitive radiotherapy for localized follicular lymphoma staged by18F-FDG PET-CT: A collaborative study by ILROG. Blood 133, 237\u2013245. https:\/\/doi.org\/10.1182\/blood-2018-04-843540 (2019).","journal-title":"Blood"},{"key":"1851_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-7-103","volume":"7","author":"M Guckenberger","year":"2012","unstructured":"Guckenberger, M., Alexandrow, N. & Flentje, M. Radiotherapy alone for stage I\u2013III low grade follicular lymphoma: Long-term outcome and comparison of extended field and total nodal irradiation. Radiat. Oncol. 7, 1\u20138. https:\/\/doi.org\/10.1186\/1748-717X-7-103 (2012).","journal-title":"Radiat. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01851-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:23:32Z","timestamp":1670070212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01851-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1851"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01851-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-384315\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22586"}}